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COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB AND
RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR
DEGENERATION (AMD):A CLINICAL AND ECONOMIC
COMPARISON OFTWOVASCULAR ENDOTHELIAL GROWTH
FACTOR INHIBITORTREATMENTS
Patel JJ, Stull MA, Bounthavong M, Christopher MLD, Foster E,
Morreale AP, Plowman BK, Boggie DT
Veterans Affairs San Diego Healthcare System (VASDHS), San Diego,
CA, USA
OBJECTIVE: To evaluate the cost-effectiveness of intravitreal
bevacizumab to ranibizumab in patients with neovascular AMD.
METHODS: A Markov Model was constructed to evaluate
incremental cost-effectiveness ratios (ICER, $/quality-adjusted
life years (QALY)) between bevacizumab and ranibizumab.
Transitional probabilities for ranibizumab were extrapolated
from two published trials, while bevacizumab probabilities were
derived using a weighted mean average of institutional clinical
outcome data as well as published studies. Utility values were
obtained from a published source. Mortality rates were deter-
mined from the Centers for Disease Control (CDC) 2003 Life
Tables. A payer perspective was taken with resource utilization
and total direct costs estimated using the Centers for Medicare
and Medicaid Services and VASDHS Decision Support System
cost data. One-thousand patients with a baseline age of 65 and
AMD diagnosis were simulated through the model for 20 years.
Sensitivity analyses were performed using univariate and proba-
bilistic sensitivity analysis (PSA) on all costs, transition probabili-
ties and utility scores. Utilities and transitional probabilities were
subject to a sensitivity analysis using beta distribution and cost
by gamma distribution. An acceptability curve was calculated to
determine the probability of cost-effectiveness of bevacizumab
to ranibizumab. RESULTS: The average cost-effectiveness ratio
(CER) for bevacizumab was $2,454 per QALY compared to
$12,327 per QALY for ranibizumab. The ICER for ranibizumab
was $258,355 for each additional QALY gained. The univariate
analysis determined the two treatments were sensitive to drug
cost. The break even point for equivalent CER was $208 for
ranibizumab (varying drug costs) and $2399 for bevacizumab
(varying drug costs). The PSA revealed an 89.8% probability of
bevacizumab being more cost-effective with a Willingness-to-Pay
(WTP). CONCLUSION: Based on a WTP deﬁned at $50,000 per
QALY, bevacizumab was more cost-effective than ranibizumab
89.8% of the time due to lower acquisition costs.
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COST–EFFECTIVE ANALYSIS OF PEGAPTANIB (MACUGEN®)
AS COMPAREDWITH RANIBIZUMAB (LUCENTIS®)
FORTREATING IN AGE–RELATED MACULAR
DEGENERATION (AMD)
Lu LY, McGhan W
University of the Sciences, Philadelphia, PA, USA
OBJECTIVE: The purpose of the research was to conduct a
cost-effectiveness model in order to analyze the value of Pegap-
tanib and Ranibizumab on the basis of the information and
resources from the previous studies. METHODS: The costs
of these modalities of AMD were calculated from published
sources. The total costs included consumptions of medical
resources and non-medical resources for AMD treatment. The
annual unit drug costs were collected from the Red Book 2007
and were multiplied by administrations per year. The efﬁcacy was
deﬁned as the loss of fewer than 15 letters from baseline visual
acuity within a year with recommendation dosage. The analysis
model was compared with placebo. We calculated Incremental
Cost Effectiveness Ratio (ICER) and plotted the cost-effectiveness
result. RESULTS: With a basic decision analysis, considering the
probability and costs of the three treatment options, the base
estimate of one year of total cost was $13,066 per person from
the pegaptanib treatment, and $31,564 for ranibizumab. The
total expected cost for placebo was $3152. The result in the
ICER model shows that pegaptanib costs $10,746 per year to get
only about 12% improvement in effectiveness compared to
placebo, while ranibizumab costs $29,244 to gain about 37%
improvement over placebo. Thus, compared to placebo, the
ICER is $934,433 per unit increase in effectiveness when patients
are treated by pegaptanib, and $80,121 in ranibizumab. CON-
CLUSION: Based on this cost-effectiveness model, both anti-
VEGF agents are costly. Ranibizumab has higher probability of
success versus in pegaptanib therapy (0.7 for pegaptanib vs. 0.95
for ranibizumab). However, the price of ranibizumab is much
higher than pegaptanib. The ICER model suggests that ranibi-
zumab maybe the ﬁrst consideration of anti-VEGF drugs because
based on this model, the ICER of ranibizumab is lower than
pegaptanib. In future studies, there should be more investigations
of quality-of-life factors.
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COST-EFFECTIVENESS OFTHETREATMENT FOR MODERATE
TO SEVERE PSORIASIS IN MEXICO: INFLIXIMAB,
ETANERCEPT AND EFALIZUMAB
Muciño E1, Rivas R2, Zapata L2
1Instituto de Salud Publica, Cuernavaca, Morelos, Mexico, 2Guia Mark,
México, DF, Mexico
OBJECTIVE: Psoriasis is a dermatological disease with major
consequences on the quality of life of patients. Biological treat-
ments for this disease have an effectiveness which is equivalent to
that of conventional drugs with fewer side effects. The objective of
this analysis was to evaluate the cost-effectiveness of the treatment
for moderate to severe psoriasis from an institutional perspective
in Mexico. METHODS: To compare the cost and the effective-
ness, a decision tree model was structured with a temporary
horizon of 12 weeks. Only costs per drug were considered for this
analysis, as the rest of the costs are similar for institutional buyers.
Comparators: inﬂiximab 5mg/kg given at weeks 0, 2, and 6;
etanercept 25 mg twice weekly, etanercept 50 mg twice weekly
and efalizumab 1mg/kg weekly. Effectiveness measure: percentage
of patients with a PASI 75 (Psoriasis Area and Severity Index)
response. Costs were estimated using prices of 2007, and an
exchange rate of x pesos/dollar was used. Costs were estimated
using 2007 prices and are expressed in USD (exchange rate of
10.93 pesos per USD). RESULTS: Costs expected per treatment
type are: $6987 inﬂiximab, $6422.70 efalizumab, $5555.40 etan-
ercept 50 mg and $2777.70 etanercept 25 mg. The percentage of
patients achieving a PASI 75 response per treatment type is: 84%
for inﬂiximab, 49% for etanercept 50 mg, 33% for etanercept
25 mg and 28% for efalizumab. The following ICERs were
obtained for inﬂiximab: $1007.70 vs. efalizumab, $8253.50 vs.
etanercept 25 mg and $4090.50 vs. etanercept 50 mg. In the three
cases, ICERs are less than three times the GDP per capita in
Mexico. CONCLUSION: Inﬂiximab is a cost-effective drug for
the treatment of moderate to severe psoriasis.
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THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS®)
INTREATING PATIENTSWITH PREDOMINANTLY CLASSIC,
MINIMALLY CLASSIC,AND OCCULT NEOVASCULAR
AGE-RELATED MACULAR DEGENERATION (AMD)
Turpcu A, Hay JW
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: Using a societal perspective, to evaluate the cost-
effectiveness of Lucentis compared to Visudyne Photodynamic
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Therapy (PDT) and best supportive care in treating patients
with AMD. METHODS: A cost-effectiveness model was created
using outcome data from the ANCHOR and MARINA clinical
trials. The model operates on quarterly cycles and a 10-year
time horizon. At baseline, Early Treatment Diabetic Retinopa-
thy Study (ETDRS) visual acuity was 55 and average age was
77 in the base case. Cost of services were obtained from the
CMS website, drug costs were obtained from ASP prices, and
visual impairment costs were based on a prospective study by
Schmier and colleagues. All costs were inﬂated to 2007 dollars
using the Health Services CPI. Utility values were based on a
time-tradeoff analysis conducted by Brown and colleagues. A
3% discount rate was used for both costs and QALYs.
RESULTS: For predominantly classic AMD, Lucentis 0.5 mg
was a dominant strategy compared to PDT and the Incremental
Cost-Effectiveness Ratio (ICER) for Lucentis 0.5 mg relative to
Lucentis 0.3 mg was $62,905/QALY. For patients with mini-
mally classic or occult AMD, Lucentis 0.5 mg was a dominant
strategy compared to best supportive care and the ICER for
Lucentis 0.5 mg relative to Lucentis 0.3 mg was $322,367/
QALY. Inﬂuential variables driving the results in this analysis
include a patient’s baseline visual acuity, costs associated with
visual impairment, and the price of Lucentis. CONCLUSION:
Despite its high treatment costs, Lucentis is a dominant strategy
compared to PDT and best supportive care primarily because it
prevents patients from reaching the highly expensive state of
blindness. Treating AMD patients with Lucentis before they
reach a legal blindness state can generate considerable cost-
savings to society.
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A COST-EFFECTIVENESS ANALYSIS OFTWOTOPICAL
OPHTHALMIC ANTIBIOTIC SOLUTIONS INDICATED FOR
THETREATMENT OF BACTERIAL CONJUNCTIVITIS
Waycaster C
Alcon Laboratories Inc, Fort Worth,TX, USA
OBJECTIVE: The objective of this study was to compare the
cost-effectiveness of moxiﬂoxacin 5 mg/ml ophthalmic solution
(MF) to polymyxin B 10,000 units/trimethoprim 1mg/ml oph-
thalmic solution (PT) for the treatment of bacterial conjunctivitis
(BC). METHODS: Physician-assessed BC early clinical cure rates
were taken on day-2 of 7 day therapy from a multi-site, random-
ized, double-masked study comparing MF to PT. The clinical
cure rates were used to calculate a number-needed-to-treat
(NNT) estimate for the most efﬁcacious alternative. NNT was
then used as the measure of effect in an incremental cost-
effectiveness analysis. Only the direct costs of drug therapy were
considered in the economic analysis. The drug costs were derived
from a standard reference source. The economic perspective was
that of the payer. No cost discounting was performed due to the
short time horizon of BC therapy. RESULTS: Thirty-two subjects
(47 eyes) received MF and 30 subjects (43 eyes) received PT. At
baseline there were no statistical differences in BC severity or
duration, patient age, gender or ethnicity between the two treat-
ment groups. After 2 days of topical ophthalmic antibiotic
therapy, 83.3% of the MF patients were deemed clinically cured
compared to 43.2% of the PT patients. The NTT for the MF
group was estimated at 2.5. The MF incremental cost-
effectiveness ratio (ICER), the cost of curing one more BC patient
earlier, was estimated at $37.28. CONCLUSION: MF cures BC
sooner than PT thus reducing the duration of illness experienced
by BC patients. Since MF is a newer and more potent antibiotic
than PT, it incurs additional costs. The incremental cost to obtain
the additional beneﬁt of an earlier cure from MF therapy is
relatively small (< $0). Further research may demonstrate a lower
cost-effectiveness ratio from MF therapy if the indirect costs of
BC are considered.
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ECONOMIC EVALUATION OF MELOXICAM SOLUTION 0.030%
RESPECT AN OPHTHALMIC SODIUM DICLOFENAC
SOLUTION 0.1% ONTHE EYES OF PATIENTSWHO
UNDERWENTTO LASIK LASER EYE SURGERY AT
THE IMMEDIATELY POST-OPERATIVETIME
Baiza L
Sophia Pharmaceuticals, Guadalajara, Jalisco, Mexico
OBJECTIVE: Compare the effectiveness and costs of the admin-
istration of an ophthalmic Meloxicam solution 0.030% with a
sodium Diclofenac solution 0.1% on the eyes of patients who
underwent to Lasik laser eye surgery at the immediately post-
operative time. METHODS: Adopting the perspective of a health
care payer, we developed a cost-effectiveness analysis. Temporary
horizon was three months. A discounting rate was not used. The
source of information of cost and effectiveness was a randomized
clinical trial. The perspective was from Mexican Institute of
social Security. The method used for cost was microcosting and
case mix. The effectiveness was measured with different end
points. The cost-effectiveness analysis was made for those vari-
ables with statistically signiﬁcant differences. The evaluation was
made with incremental analysis and net beneﬁts approach. The
sensitivity analyses was of one way, two ways and probabilistic.
RESULTS: The highest cost was with Diclofenac solution
(USD$9.29) that was 5.9% higher than Meloxicam ($8.74) the
measured efﬁcacy named Flare and ciliary injection was superior
with Meloxicam compared with Diclofenac 148 vs. 149 for Flare
and 150 vs 153 respectively (p < 0.0001) for ciliary injection, the
cost for success obtained with Meloxicam was of USD$8.74 and
USD$9.29 with Diclofenac, the incremental analysis show that
Meloxicam is dominant over Diclofenac. Health Net Beneﬁts,
Monetary Net Beneﬁts and the Acceptability curves were favour-
able for Meloxicam independent the willingness to pay.
CONCLUSION: The Meloxicam solution was dominant over
Diclofenac in the application on the ocular surface in patients
who underwent to Lasik laser eye surgery in the immediate
postoperative period. The sensitivity analysis was a robust basis
for the study.
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COST-EFFECTIVENESS OFTHE BIOLOGIC AGENTS UTILIZED
INTHETREATMENT OF CHRONIC PLAQUE PSORIASIS:
A MARKOV MODEL
Goldberg LD1, Feldman SR2, Marshall TS3, Jaracz E3
1Goldberg, MD & Associates, Battle Ground,WA, USA, 2Wake Forest
University School of Medicine,Winston Salem, NC, USA, 3Astellas
Pharma US, Deerﬁeld, IL, USA
OBJECTIVE: It is the objective of this study to estimate the cost
per treatment success over a one-year timeframe of the ﬁve
biologic therapies used to treat patients with moderate to severe
psoriasis in the United States. METHODS: A Markov model was
developed to compare the relative cost components in psoriasis
treatment with biologics. Drug costs were based on wholesale
acquisition cost with consideration of net contractual discounts
and patient co-share or co-payment. Clinical efﬁcacy, for both
short-term (12 weeks) and longer-term (24+ weeks) treatment,
was based on the published peer-reviewed literature. The primary
economic endpoint was the cost of therapy (deﬁned as the cost of
drugs, laboratory, infusion, and professional services) per 75%
improvement from baseline in the Psoriasis Area and Severity
Index score (PASI 75) achieved. Analysis was conducted for each
Abstracts A289
